Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.91 USD

105.91
175,375

-0.54 (-0.51%)

Updated Nov 11, 2024 10:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Roche Posts Solid Sales for First 9 Months of '19, Ups View

by Zacks Equity Research

Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

Roche Announces Positive Late-Stage Data on Rituxan in PV

by Zacks Equity Research

Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.

Kinjel Shah headshot

Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

by Kinjel Shah

FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

Ekta Bagri headshot

Wet AMD Space in Focus: New Drug Approvals & Key Advancements

by Ekta Bagri

The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval

by Zacks Equity Research

Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.

Is Novartis (NVS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (NVS) Outperforming Other Medical Stocks This Year?

Biogen Strengthens MS & SMA Portfolio as Competition Lurks

by Zacks Equity Research

Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.

AstraZeneca's Fasenra Gets FDA Nod for Self-Administration

by Zacks Equity Research

The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study

Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx

by Zacks Equity Research

The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY

by Kinjel Shah

J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.

Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

by Zacks Equity Research

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

Novartis Reports Additional Data on Spondylitis Drug Cosentyx

by Zacks Equity Research

Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.

Novartis (NVS) Announces Data on Asthma Drugs & Kisqali

by Zacks Equity Research

Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.

Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.

AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug

by Zacks Equity Research

AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.

Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance

by Zacks Equity Research

Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.

Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late

by Zacks Equity Research

Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Here's Why AstraZeneca (AZN) is Outperforming Its Industry

by Zacks Equity Research

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

by Zacks Equity Research

Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

Incyte Treats First Patient in Phase III Vitiligo Study

by Zacks Equity Research

Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.

Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy

by Zacks Equity Research

Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex

Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval

by Zacks Equity Research

Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates

by Kinjel Shah

FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.

Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

by Zacks Equity Research

Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.